EP300/CREBBP acetyltransferase inhibition limits steroid receptor and FOXA1 signaling in prostate cancer cells

Jasmin Huttunen,Niina Aaltonen,Laura Helminen,Kirsi Rilla,Ville Paakinaho

DOI: https://doi.org/10.1007/s00018-024-05209-z

IF: 8

2024-04-03

Cellular and Molecular Life Sciences

Abstract:The androgen receptor (AR) is a primary target for treating prostate cancer (PCa), forming the bedrock of its clinical management. Despite their efficacy, resistance often hampers AR-targeted therapies, necessitating new strategies against therapy-resistant PCa. These resistances involve various mechanisms, including AR splice variant overexpression and altered activities of transcription factors like the glucocorticoid receptor (GR) and FOXA1. These factors rely on common coregulators, such as EP300/CREBBP, suggesting a rationale for coregulator-targeted therapies. Our study explores EP300/CREBBP acetyltransferase inhibition's impact on steroid receptor and FOXA1 signaling in PCa cells using genome-wide techniques. Results reveal that EP300/CREBBP inhibition significantly disrupts the AR-regulated transcriptome and receptor chromatin binding by reducing the AR-gene expression. Similarly, GR's regulated transcriptome and receptor binding were hindered, not linked to reduced GR expression but to diminished FOXA1 chromatin binding, restricting GR signaling. Overall, our findings highlight how EP300/CREBBP inhibition distinctively curtails oncogenic transcription factors' signaling, suggesting the potential of coregulatory-targeted therapies in PCa.

cell biology,biochemistry & molecular biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to limit the effectiveness of steroid receptors (such as androgen receptor AR and glucocorticoid receptor GR) and FOXA1 signal transduction by inhibiting EP300/CREBBP acetyltransferase activity in prostate cancer cells. Specifically, the study aims to explore the genome - wide effects of EP300/CREBBP acetyltransferase inhibition on AR and GR signaling pathways in prostate cancer cells, and how these inhibitory effects affect FOXA1 binding and function. This research is of great significance for the development of new strategies for the treatment of resistant prostate cancer, especially in the context of resistance to androgen deprivation therapy (ADT) and other AR - targeted therapies.

### Research Background
- **Androgen Receptor (AR)**: AR is the main target for prostate cancer (PCa) treatment, but patients often face treatment failure due to the development of resistance.
- **Mechanisms of Treatment Resistance**: Resistance mechanisms include overexpression of AR splicing variants, altered activity of transcription factors (such as glucocorticoid receptor GR and FOXA1), etc.
- **Co - regulatory Factors**: These transcription factors depend on common co - regulatory factors, such as EP300/CREBBP, which suggests the potential for co - regulatory factor - targeted therapy.

### Research Objectives
- **Explore the Effects of EP300/CREBBP Acetyltransferase Inhibition**: The study uses genome - wide techniques (such as ChIP - seq, ATAC - seq, and RNA - seq) to evaluate the effects of EP300/CREBBP acetyltransferase inhibition on AR and GR signaling pathways.
- **Reveal the Inhibition Mechanisms**: Explore how EP300/CREBBP acetyltransferase inhibition affects gene expression and chromatin binding of AR and GR, as well as chromatin binding of FOXA1.

### Main Findings
- **AR Signaling Pathway**: EP300/CREBBP acetyltransferase inhibition significantly disrupts the AR - regulated transcriptome and reduces AR gene expression and receptor chromatin binding.
- **GR Signaling Pathway**: Similarly, the GR - regulated transcriptome and receptor binding are also inhibited, but this is not due to a reduction in GR gene expression, but rather due to a reduction in FOXA1 chromatin binding, thereby limiting GR signal transduction.
- **The Role of FOXA1**: EP300/CREBBP acetyltransferase inhibition not only limits steroid receptor signaling, but also significantly reduces FOXA1 activity.

### Conclusion
The research results show that EP300/CREBBP acetyltransferase inhibition can effectively limit steroid receptor and FOXA1 signal transduction in prostate cancer cells, which provides an important theoretical basis for the development of new treatment strategies. Especially for treatment - resistant prostate cancer, this inhibitory strategy may have potential clinical application value.